Skip to content
Clinical trial diversity is the cornerstone of equal access to care, but clinical trial participants are still overwhelmingly white. Data released by the Food […]
Clinical trial diversity is essential for equal access and good medicine Read More »
It is no secret that the United States has the worst maternal mortality rates in the developed world, especially among Black women. “Every two
It’s a great time to talk about maternal health Read More »
The opioid epidemic has hit the United States hard in the last 25 years, killing more than 70,000 in 2019 alone, according to the
FDA draft guidance on non-opioid analgesics ‘inadequate’ Read More »
Life sciences companies that have chosen to locate in the old Philadelphia Navy Yard received a visit from two members of Congress, Rep. Mary
Members of Congress tour Philadelphia’s new innovation hub Read More »
A “march-in” petition filed under the Bayh-Dole Act, asking NIH to give competing drug companies the license to produce the prostate cancer drug Xtandi
Panel says attack on the Bayh-Dole Act threatens small businesses Read More »
Everyone’s talking about pharmacy benefit managers (PBMs)—including the Federal Trade Commission (FTC)—but what exactly are PBMs and why do they matter in the context
What are PBMs, anyway? Read More »
“Unfortunately, people of African descent are significantly underrepresented in clinical trials, meaning that products and regimens approved based on data from people of other
BVGH AC³T is changing lives, one clinical trial at a time Read More »
Bio.News interviewed Yvonne Greenstreet, who took the reins as CEO of Alnylam in January 2022, making her one of a small number of Black
Alnylam CEO Greenstreet: ‘You can go faster alone, but you go far together’ Read More »
The pandemic showed us that we can develop vaccines and other drugs in a short time, and get a lot of people vaccinated, but
POLITICO’s Health Care Summit: The Many Legacies of COVID Read More »
A new federal research agency would seek solutions for the most challenging diseases, clinical trials would become more diverse, and patients would get new
The Cures 2.0 bill: ‘Frankly, patients can’t wait’ Read More »
